← Theranexus SA (ALTHX.PA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Theranexus SA (ALTHX.PA)
Pharmaceutical Preparations · market cap $53M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Theranexus SA (ALTHX.PA) is a small French pharmaceutical company with 12 employees and a market cap of approximately $49M. Its lead asset, THN102 300/3, is in Phase 2 development for narcolepsy, with a second dosage variant in Phase 2 for Parkinson's Disease. The company has minimal disclosed financials, no upcoming catalysts on the calendar, and a single analyst covering the stock with a price target of $5.80.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| THN102 300/3 | Phase 2 | Narcolepsy |
| THN102 Dosage A | Phase 2 | Parkinson Disease |
| Miglustat 100 milligrams (mg) Oral Capsule | Phase 2 | Batten Disease |
Price & technical context
3-month
-9.2%
6-month
+1.9%
12-month
+19.4%
52-wk range
$1.57–$4.59
vs 50-day MA
-19.0%
vs 200-day MA
-5.0%
Realized vol
78.4%
Max drawdown
-55.0%
Daily closes through 2026-10-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALTHX.PA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.